Beyond The Numbers: 6 Analysts Discuss IDEXX Laboratories Stock
Portfolio Pulse from Benzinga Insights
IDEXX Laboratories (NASDAQ:IDXX) has received mixed analyst ratings over the past three months, with 6 analysts offering diverse outlooks. The average 12-month price target is $546.17, with a high of $650.00 and a low of $460.00, reflecting a slight decrease from the previous average of $548.00. Analysts from firms including Goldman Sachs, Piper Sandler, JP Morgan, Barclays, and Stifel have updated their ratings and price targets, indicating varying levels of confidence in the company's performance. IDEXX develops diagnostic products for pets and livestock and has shown strong financial health with notable revenue growth, net margin, ROE, and ROA, but carries a higher debt-to-equity ratio than the industry average.
January 17, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
IDEXX Laboratories has received a range of analyst ratings, with an average 12-month price target of $546.17. The company's strong financial metrics may positively influence investor sentiment, despite a slight decrease in the average price target and a high debt-to-equity ratio.
The mixed analyst ratings and the slight decrease in the average price target suggest a neutral short-term impact on IDXX's stock price. The company's strong financial health indicators, such as revenue growth, net margin, ROE, and ROA, may counterbalance the concerns over its higher debt-to-equity ratio. The overall impact is likely to be neutral as the market digests the diverse opinions and the strong financial performance.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100